Glutamatergic drugs for schizophrenia

The Cochrane Database of Systematic Reviews
H J TuominenK Wahlbeck

Abstract

It has been shown that central nervous system dopamine can play a major role in the pathophysiology of schizophrenia. Brain glutamate is thought to mediate symptoms in schizophrenia due to the influence of glutamate neurons on the dopaminergic transmission in the brain. It might be possible to decrease negative symptoms and the cognitive impairment of people with schizophrenia by treatment with glutamatergic drugs. To determine the efficacy of glutamatergic drugs in the treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's Trials Register (May 2002 and October 2003), inspected references of all identified studies and contacted relevant authors. We included all randomised controlled trials in which glutamatergic medication was administered to people with schizophrenia. We reliably selected studies, quality rated them and extracted data. For dichotomous data, we estimated relative risks (RR), with the 95% confidence intervals (CI). Where possible, we calculated the number needed to treat/harm statistic (NNT/H) and used intention-to-treat analysis. We included eighteen short-term trials with 358 randomised participants. The single studies were small with numbers of participants ranging between six and 51. All ...Continue Reading

References

Nov 1, 1992·Journal of General Internal Medicine·G W DivineL M Frazier
Jun 1, 1991·Clinical Neuropharmacology·R B RosseS I Deutsch
Aug 1, 1990·Clinical Neuropharmacology·R B RosseS I Deutsch
Feb 1, 1990·Journal of Clinical Psychopharmacology·J CostaS G Potkin
Jan 15, 1988·Biological Psychiatry·R Waziri
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Comprehensive Psychiatry·J SimeonD Ponce
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Feb 1, 1995·Journal of Clinical Psychopharmacology·R L Borison
May 10, 1995·Annals of the New York Academy of Sciences·I ZylbermanS R Zukin
Aug 1, 1995·The American Journal of Psychiatry·D C GoffJ T Coyle
Jan 1, 1994·Journal of Neural Transmission. General Section·N G CascellaE Smeraldi
Nov 1, 1994·The Journal of Nervous and Mental Disease·J P LindenmayerS Grochowski
Aug 1, 1994·The American Journal of Psychiatry·D C JavittJ P Lindenmayer
Oct 1, 1996·Clinical Neuropharmacology·R B RosseS I Deutsch
Nov 9, 1996·BMJ : British Medical Journal·D G Altman, J M Bland
Nov 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·U Heresco-LevyD Kelly
Dec 1, 1996·The American Journal of Psychiatry·D C GoffJ T Coyle
Dec 15, 1996·Biological Psychiatry·B N van BerckelR S Kahn
Sep 26, 1997·BMJ : British Medical Journal·J M Bland, S M Kerry
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jun 20, 1998·BMJ : British Medical Journal·B Sibbald, C Roberts
Dec 4, 1998·Biological Psychiatry·G TsaiJ T Coyle
Jan 19, 1999·Archives of General Psychiatry·U Heresco-LevyM Lichtenstein
Jan 19, 1999·The American Journal of Psychiatry·S G PotkinB Gulasekaram
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B N van BerckelR S Kahn
Dec 3, 1999·Journal of Clinical Pharmacy and Therapeutics·A A NoorbalaH Amini-Nooshabadi
Apr 4, 2000·Biological Psychiatry·A ParwaniJ P Rotrosen
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M MarshallM Fenton
Apr 28, 2000·The American Journal of Psychiatry·A E EvinsD C Goff
Jul 25, 2000·Neurochemical Research·S H Snyder, P M Kim
Dec 21, 2000·Current Psychiatry Reports·D C Javitt
Feb 7, 2001·The American Journal of Psychiatry·P D Harvey, R S Keefe
Feb 15, 2001·Archives of General Psychiatry·B KirkpatrickW T Carpenter
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·A CarlssonM L Carlsson
Apr 3, 2001·The International Journal of Neuropsychopharmacology·Uriel Heresco-LevyJonathan Shimoni
Apr 20, 2001·JAMA : the Journal of the American Medical Association·D MoherUNKNOWN CONSORT Group (Consolidated Standards of Reporting Trials)
May 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E J DuncanJ P Rotrosen
Sep 5, 2001·The American Journal of Psychiatry·D C Goff, J T Coyle
Oct 11, 2001·Journal of Clinical Psychopharmacology·D C GoffG Lynch
Jan 25, 2002·The International Journal of Neuropsychopharmacology·D C JavittS R Zukin
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Guochuan Tsai, Joseph T Coyle

❮ Previous
Next ❯

Citations

Jul 19, 2008·Lancet Neurology·Lorraine V KaliaMichael W Salter
May 9, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert A SweetDavid A Lewis
Sep 18, 2014·BMC Psychiatry·Diarmid Sinclair, Clive E Adams
May 11, 2015·The Cochrane Database of Systematic Reviews·Rasmita OriDan J Stein
Nov 14, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey A LiebermanUNKNOWN MEM-MD-29 Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The Cochrane Database of Systematic Reviews
S LeuchtW Kissling
The Cochrane Database of Systematic Reviews
C RummelS Leucht
The Cochrane Database of Systematic Reviews
P Tharyan
© 2022 Meta ULC. All rights reserved